Chiesi Group
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 4 disclosed transactions, Chiesi Group concentrates its licensing activity in RareDisease, Cardiovascular, and InfectiousDisease. Chiesi Group pays a 0.70x discount to market median. Their most common deal structure is License, with an average disclosed value of $874M. Most recent activity: 2026.
Pipeline coverage & gaps
Chiesi Group has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 2 | $93M | $556M |
| Acquisition | 1 | — | $1.9B |
| Collaboration | 1 | — | $486M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | Ekterly | KalVista | hereditary angioedema | unknown | — | $1.9B |
| 2024 | seralutinib | Gossamer Bio | PAH and PH-ILD | phase_2 | — | $486M |
| 2024 | pulmonary_hypertension | Gossamer Bio | pulmonary_hypertension | phase_3 | $160M | $486M |
| 2019 | Pegunigalsidase alfa (Elfabrio) | Protalix BioTherapeutics | Fabry Disease | phase_3 | $25M | $625M |
How this is computed
For each Chiesi Group deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.536, clamped to [0.7, 1.5].